Related Experiment Video
Updated: Sep 11, 2025
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
Published on: November 9, 2018
Programmed cell death signatures-driven microglial transformation in Alzheimer's disease: single-cell transcriptomics
Mi-Mi Li1, Ying-Xia Yang1, Ya-Li Huang1
1Department of Neurology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Background:
This study aims to develop and validate a programmed cell death signature (PCDS) for predicting and classifying Alzheimer's disease (AD) using an integrated machine learning framework. We further explore the role of S100A4 in AD pathogenesis, particularly in microglia.
Methods:
A total of one single-cell RNA sequencing (scRNA-seq) and four bulk RNA-seq datasets from multiple GEO datasets were analyzed. Weighted Gene Co-expression Network Analysis (WGCNA) was utilized to identify PCD-related genes. An integrated machine learning framework, combining 12 algorithms was used to construct a PCDS model. The performance of PCDS was validated using multiple independent cohorts. In vitro experiments using BV2 microglia were conducted to validate the role of S100A4 in AD, including siRNA transfection, Western blot, qRT-PCR, cell viability and cytotoxicity assay, flow cytometry, and immunofluorescence.
Results:
ScRNA-seq analysis revealed higher PCD levels in microglia from AD patients. Seventy-seven PCD-related genes were identified, with 70 genes used to construct the PCDS model. The optimal model, combining Stepglm and Random Forest, achieved an average AUC of 0.832 across five cohorts. High PCDS correlated with upregulated pathways related to inflammation and immune response, while low PCDS associated with protective pathways. In vitro, S100A4 knockdown in AbetaO-treated BV2 microglia improved cell viability, reduced LDH release, and partially alleviated apoptosis. S100A4 inhibition attenuated pro-inflammatory responses, as evidenced by the reduced expression of pro-inflammatory mediators (IL-6, iNOS, TNF-α) and promoted an anti-inflammatory state, indicated by increased expression of markers such as IL-10, ARG1, and YM1/2. Furthermore, S100A4 knockdown mitigated oxidative stress, restoring mitochondrial function and decreasing ROS levels.
Conclusion:
This study developed a robust PCDS model for AD prediction and identified S100A4 as a potential therapeutic target. The findings highlight the importance of PCD pathways in AD pathogenesis and provide new insights for early diagnosis and intervention.
Insights
This study developed a programmed cell death signature (PCDS) to predict Alzheimer's disease (AD) and identified S100A4 as a potential therapeutic target. The PCDS model shows promise for early AD diagnosis and intervention strategies.
Area of Science:
- Neuroscience
- Genomics
- Computational Biology
Background:
- Alzheimer's disease (AD) pathogenesis involves complex cellular processes, including programmed cell death (PCD).
- Microglia play a critical role in neuroinflammation and AD progression.
- Identifying reliable biomarkers for AD is crucial for early diagnosis and treatment.
Purpose of the Study:
- To develop and validate a novel programmed cell death signature (PCDS) for predicting and classifying Alzheimer's disease (AD).
- To explore the specific role of the S100A4 protein in AD pathogenesis, particularly within microglia.
- To establish a machine learning framework for robust AD biomarker discovery.
Main Methods:
- Integrated analysis of single-cell and bulk RNA sequencing data from multiple cohorts.
- Weighted Gene Co-expression Network Analysis (WGCNA) to identify PCD-related genes.
- Development and validation of a PCDS model using an ensemble of 12 machine learning algorithms.
- In vitro validation of S100A4 function in BV2 microglia using siRNA, Western blot, qRT-PCR, and functional assays.
Main Results:
- A PCDS model, combining Stepglm and Random Forest algorithms, achieved an average AUC of 0.832 across five independent cohorts.
- High PCDS scores correlated with upregulated inflammatory and immune response pathways in AD microglia.
- S100A4 knockdown in microglia reduced apoptosis, inflammation, and oxidative stress, suggesting a protective role.
Conclusions:
- A robust PCDS model was successfully developed for AD prediction, offering potential for early diagnosis.
- S100A4 emerged as a significant factor in AD pathogenesis and a potential therapeutic target.
- These findings underscore the importance of PCD pathways in AD and provide novel insights for therapeutic interventions.
